Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$24.46 USD
-0.03 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.43 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Mirum Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 186 | 77 | 19 | 0 | 0 |
Cost Of Goods | 47 | 12 | 2 | 0 | 0 |
Gross Profit | 139 | 65 | 17 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 248 | 196 | 191 | 104 | 55 |
Income After Depreciation & Amortization | -109 | -131 | -173 | -104 | -55 |
Non-Operating Income | -38 | 5 | 107 | 1 | 2 |
Interest Expense | 15 | 16 | 18 | 0 | 0 |
Pretax Income | -162 | -142 | -84 | -103 | -53 |
Income Taxes | 1 | -6 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -163 | -136 | -84 | -103 | -53 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -163 | -136 | -84 | -103 | -53 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -97 | -128 | -172 | -104 | -55 |
Depreciation & Amortization (Cash Flow) | 12 | 4 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -109 | -131 | -173 | -104 | -55 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 40.89 | 33.98 | 30.32 | 25.25 | 11.49 |
Diluted EPS Before Non-Recurring Items | -2.92 | -4.02 | -5.58 | -4.09 | -4.58 |
Diluted Net EPS (GAAP) | -4.00 | -4.02 | -2.77 | -4.09 | -4.58 |
Fiscal Year end for Mirum Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 69.55 | 47.73 | 37.50 | 31.60 |
Cost Of Goods | NA | 25.02 | 10.23 | 6.81 | 4.98 |
Gross Profit | NA | 44.53 | 37.50 | 30.69 | 26.62 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 77.12 | 62.65 | 54.96 | 53.77 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -32.59 | -25.15 | -24.27 | -27.15 |
Non-Operating Income | NA | 0.71 | 5.38 | -45.72 | 1.46 |
Interest Expense | NA | 3.56 | 3.57 | 3.73 | 4.24 |
Pretax Income | NA | -35.43 | -23.34 | -73.72 | -29.93 |
Income Taxes | NA | 0.23 | 0.25 | 0.32 | 0.20 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -35.66 | -23.59 | -74.04 | -30.13 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -35.66 | -23.59 | -74.04 | -30.13 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 40.89 | 41.10 | 38.11 | 37.68 |
Diluted EPS Before Non-Recurring Items | NA | -0.66 | -0.57 | -0.92 | -0.80 |
Diluted Net EPS (GAAP) | NA | -0.69 | -0.57 | -1.94 | -0.80 |